Evaluation of the level of serum Interleukins (IL-2, IL-4, IL-15 andIL-17) and its relationship with disease severity in patients with alopecia areata

BackgroundAlopecia areata (AA) is a hair disease that causes hair loss without scarring. The etiopathogenesis of AA has not been fully understood yet.ObjectiveTo determine serum interleukin levels (IL-2, IL-4, IL-15, and IL-17) in patients diagnosed with alopecia areata and to investigate the relationship of IL levels with the duration and severity of alopecia areata and the response to tofacitinib therapy.MethodsPatients (≥16 years old) diagnosed with alopecia areata and healthy individuals as a control group was enrolled. Baseline serum interleukin levels of the patients and controls were measured. In the patient group receiving tofacitinib therapy, serum interleukin levels were measured again after 6 months. Disease severity for alopecia areata was assessed using the Severity of Alopecia Tool.ResultsSixty-one AA patients and 30 healthy individuals were included; they were comparable regarding age and sex. The mean disease duration for AA was 7 ± 6 years and the baseline mean Severity of Alopecia Tool score was 71 ± 30 (range, 20–100). Baseline IL-2, IL-4 and IL-15 levels were significantly higher in the patient group than those in the control group (p < 0.001 for each). No significant correlation was found between the baseline interleukin levels and either disease duration or disease severity (baseline Severity of Alopecia Tool score). Among the patients receiving tofacitinib (n = 22), all interleukin levels significantly decreased after treatment. However, no significant relationship between the change in interleukin levels and the change in the Severity of Alopecia Tool scores was observed after tofacitinib treatment.Study limitationsThis is a monocentric study conducted in a single university hospital.ConclusionHigh interleukin levels in alopecia areata patients and the significant decrease with treatment support the idea that interleukins have a role in pathogenesis. Nevertheless, no relationship could be demonstrated between IL levels and disease duration or severity.     

IL-28B基因突变与慢性丙型肝炎治疗应答的相关性研究

目的 探讨白介素28B(IL-28B)基因型与慢性丙型肝炎(CHC)患者抗病毒治疗反应的相关性.方法 220例CHC患者均接受聚乙二醇干扰素(peg-IFN)联合利巴韦林(RBV)治疗48周,随访至停药后24周.检测IL-28B(rs8099917)位点,比较IL-28B基因型与抗病毒疗效的关系,评估IL-28B单核苷酸多态性(SNP)在CHC患者治疗应答中的作用.结果 TT、TG和GG基因型在持续应答组(SVR)中的比例分别是71.4％、25.0％和3.6％;在无应答组(NR)分别是15.8％、60.5％和23.7％;在复发组(RP)分别是38.1％、52.3％和9.6％;三组之间比较差异具有统计学意义(P＜0.001).NR与SVR组内基因型比较,TG vsTT的OR为7.67(P＜0.001,95％ CI:2.91～20.56),差异有统计学意义.RP与SVR组内基因型比较,TG vsTT的OR为3.10(P＜0.01,95％ CI:1.41～6.36),差异有统计学意义.结论 IL-28B(rs8099917)基因型与慢丙肝患者抗病毒应答密切相关,可作为治疗前的一个重要的预测因子.     

加味玉屏风散对慢性阻塞性肺疾病急性加重期患者肺功能和细胞因子的影响

目的观察加味玉屏风散对慢性阻塞性肺疾病(COPD)急性加重期患者肺功能和血清中白细胞介素(IL)-17和IL-8的影响,为加味玉屏风散干预治疗COPD提供理论依据。方法将62例急性COPD患者随机分为加味玉屏风散治疗组(31例)和病例对照组(31例)。对照组给予常规治疗;治疗组在常规治疗基础上加用加味玉屏风散,8周后观察2组临床疗效以及治疗前后的肺功能第1秒用力呼气量占预计值百分比(FEV1%)、总气道阻力(R5)和共振频率变化;采用酶联免疫吸附试验法(ELISA)测定血清IL-8I、L-17的水平。结果①加味玉屏风散治疗组的总有效率(87%)较对照组总有效率(68%)升高,且差异有统计学意义(P<0.05)。②2组的FEV1%经过治疗后,均较治疗前升高,差异有统计学意义(P<0.05);治疗组较对照组FEV1%升高,且差异有统计学意义(P<0.05);R5、共振频率2组治疗后较治疗前明显下降,且治疗组较病例对照组下降,差异有统计学意义(P<0.05)。③2组血清IL-17I、L-8水平治疗后均较治疗前明显下降(P<0.05);治疗后治疗组较对照组有明显下降,差异有统计学意义(P<0.05)。结论中药玉屏风散对COPD患者可下调IL-17I、L-8水平,并改善患者肺功能。     

两种麻醉方法对胃癌手术患者血清T淋巴细胞亚群及炎性因子水平的影响

目的比较全身麻醉与全身麻醉复合硬膜外腔阻滞麻醉对胃癌手术患者血清T淋巴细胞亚群及白细胞介素-6（IL-6）、白细胞介素-10（IL-10）、肿瘤坏死因子-α（TNF-α）水平的影响。方法选择60例胃癌手术患者,按数字表法随机分为I组和Ⅱ组各30例,I组采用全身麻醉方法,Ⅱ组采用全身麻醉复合硬膜外腔阻滞麻醉方法,分别于麻醉前、麻醉后2h、术后1d和术后6d检测两组血清CD3＋、CD4＋、CD4＋／CD8＋及IL-6、IL-10、TNF-α的水平,并进行比较。结果两组麻醉后2h、术后1d血清CD3＋、CD4＋、CD4＋／CD8＋水平均较麻醉前明显下降（均P〈0．05）,且I组下降水平大于Ⅱ组（P〈0.05）;两组麻醉后2h血清IL-6水平均明显升高（均P〈0．05）,两组IL-10、TNF-α水平无明显变化（均P〉0．05）。术后6d两组各项观察指标均恢复至术前水平。结论全身麻醉复合硬膜外腔阻滞麻醉对胃癌手术患者术后免疫功能有一过性抑制作用,且抑制程度轻于全麻身麻醉方法,而对患者的炎性反应影响较小。     

红霉素在早产鼠高氧肺损伤中对白细胞介素6、8及γ-谷氨酰半胱氨酸合成酶表达的影响

目的 探讨红霉素在早产鼠高氧肺损伤中对白细胞介素6 （IL-6）,IL-8及γ-谷氨酰半胱氨酸合成酶（γ-GCS）的干预作用.方法 96只早产新生SD大鼠生后1d分为四组：Ⅰ组空气暴露＋生理盐水、Ⅱ组空气暴露＋红霉素、Ⅲ组高氧暴露＋生理盐水、Ⅳ组高氧暴露＋红霉素,每组各24只.四组分别于高氧或空气暴露后1、7、14d处死取肺组织做病理学检查.采取双抗体夹心酶联免疫吸附试验分析肺组织匀浆细胞因子IL-6、IL-8和γ-GCS的水平,并采取半定量逆转录聚合酶链反应测定γ-GCS mRNA的表达.结果 Ⅰ、Ⅱ组肺组织无明显病理改变,Ⅲ组肺泡炎性改变及水肿较Ⅳ组更为明显.Ⅳ组γ-GCS水平在7、14 d较Ⅲ组降低,但是γ-GCS mRNA表达较γ-GCS mRNA均明显增强（P均＜0.05）.Ⅲ组1、7、14 d IL-6及IL-8水平较Ⅰ组均显著增强（P均＜0.05）.Ⅳ组IL-6水平在1、7、14d与Ⅲ组比较,差异均有统计学意义（P均＜0.05）,而IL-8水平仅在7、14d较Ⅲ组明显下降（P均＜0.05）.结论 氧化爆发诱导的炎症介质IL-6及IL-8参与高氧肺损伤发病过程,红霉素可抑制其释放,影响γ-GCS活性从而提高谷胱甘肽抗氧化能力.     

左归丸含药血清对成骨细胞IL-1、IL-6和COX-2表达的影响

目的通过观察左归丸含药血清对成骨细胞白细胞介素-1(IL-1)、白细胞介素-6(IL-6)和环加氧酶-2(COX-2)表达的影响,探讨其治疗骨质疏松症的作用机制。方法体外分离、培养成骨细胞,实验分为3组:正常血清组、卵巢切除(OVX)血清组和OVX含药血清组。采用免疫组化法,检测成骨细胞IL-1、IL-6和COX-2的表达。结果OVX血清组成骨细胞IL-1、IL-6和COX-2的表达明显强于正常血清组,而OVX含药血清组的表达较OVX血清组明显减弱,与正常血清组比较,则无显著性差异。结论在去势状态下,左归丸可能是通过抑制成骨细胞IL-1、IL-6和前列腺素E2(PGE2)的分泌,进而达到治疗骨质疏松的作用。     

Effect of Liandouqingmai recipe on quality of life and inflammatory reactions of patients with coronary heart disease

OBJECTIVE： To observe the effect of Liandouqingmai recipe（Chinese herbal medicine compound preparation） on the quality of life（QOL） and inflammatory reaction of patients with coronary heart disease（CHD）.METHODS： A total of 101 CHD patients were randomized into two groups： treatment group（n=45）receiving standard treatment for CHD plus Liandouqingmai recipe, and control group（n=56） receiving standard treatment only. The control group contained 16 normal healthy subjects. Changes in hs-C-reactive protein（CRP）, peripheral blood leucocytes（PBL）, and interleukin（IL）-6 and IL-10 levels were measured. The Seattle Angina Questionnaire（SAQ） was used to determine patient QOL before and after treatment for 2 weeks.RESULTS： Before treatment, SAQ scores [physical limitation（PL）, angina stability（AS）, angina frequen-cy（AF）, treatment satisfaction（TS）, and disease perception（DP）] were not statistically different between groups. After treatment, AS and DP levels of controls were significantly increased compared with the other groups, while PL, AS, AF, TS, and DP levels of the treatment group were significantly increased compared with controls. Treatment group SAQ scores（PL, AS, AF, TS, and DP） were significantly higher than for controls. CHD patient IL-6 and IL-10 levels were significantly higher than controls.Before treatment, mean levels of IL-6, hs-CRP and PBL of the two groups were not statistically different. After treatment, mean levels of IL-6, IL-10,hs-CRP and PBL of the two groups were significantly decreased compared with their before treatment values, and levels of IL-6, hs-CRP, and PBL of the treatment group were lower than controls. Although mean IL-10 levels of both groups decreased, there was no significant difference in between-group and in-group comparisons before and after treatment. Mean levels of IL-6 and IL-10 in the normal group were lower than in CHD patients.SAQ scores of QOL were negatively associated with the inflammatory index（IL-6/IL     

重症肌无力患者白细胞介素17、21、23检测及其临床意义

目的 检测重症肌无力患者血清白细胞介素（IL）-17、21、23的表达水平,探讨IL-17、IL-21和IL-23水平与重症肌无力发病的关系.方法 采用酶联免疫分析法检测45例重症肌无力患者血清IL-17、IL-21和IL-23水平,并与正常对照组比较.结果 重症肌无力组IL-17、IL-21和IL-23水平高于对照组（重症肌无力组IL-17、IL-21和IL-23中位数分别为5.86 pg/ml、198.15 pg/ml、224.04 pg/ml,对照组中位数分别为5.20 pg/ml、80.27 pg/ml、59.46 pg/ml）,差异具有统计学意义（P＜0.05）.眼肌型与全身型相比IL-17、IL-21、IL-23水平无显著性差异（P＞0.05）.胸腺疾病组与非胸腺疾病组IL-17、IL-21、IL-23水平无显著性差异（P＞0.05）.结论 IL-17、IL-21和IL-23在重症肌无力发病的免疫调节过程中发挥一定作用.